Cargando…
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Risankizumab (Skyrizi(®); risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate...
Autor principal: | Blair, Hannah A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475056/ https://www.ncbi.nlm.nih.gov/pubmed/32632826 http://dx.doi.org/10.1007/s40265-020-01357-1 |
Ejemplares similares
-
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021) -
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022) -
Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019) -
Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019) -
Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)